Severin Schwan, Roche CEO (Sebastien Bozon/AFP via Getty Images)
April 25, 2022 02:00 PM EDTUpdated 03:22 PM
Pharma

A fail­ure in breast can­cer and now a de­lay for Po­livy? Roche can't catch a break

Nicole DeFeudis

Editor

De­spite a sales boost last quar­ter, CEO Sev­erin Schwan not­ed sev­er­al set­backs in a pre­sen­ta­tion for in­vestors on Mon­day, in­clud­ing a de­lay in the phar­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Roche’s Parkin­son’s drug flunks sec­ond mid-stage tri­al

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

Sang­amo strikes an­oth­er brain-tar­get­ing AAV part­ner­ship, this time with Astel­las

Bris­tol My­ers pays $100M up­front to col­lab­o­rate with Leqem­bi orig­i­na­tor in Alzheimer's

A service from the Financial Times